Published in final edited form as:

J Toxicol Sci. 2013 ; 38(3): 349–354.

The *CYP3A4* intron 6 C>T polymorphism (*CYP3A4*22*) is associated with reduced *CYP3A4* protein level and function in human liver microsomes

Maho Okubo¹, Norie Murayama¹, Makiko Shimizu¹, Tsutomu Shimada², F. Peter Guengerich³, and Hiroshi Yamazaki^{1,*}

¹Showa Pharmaceutical University, Machida, Tokyo 194-8543, Japan

²Graduate School of Life and Environmental Sciences, Osaka Prefecture University, Izumisano, Osaka 598-8531, Japan

³Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-0146, USA

Abstract

Effects of the *CYP3A4* intron 6 C>T (*CYP3A4*22*) polymorphism, which has recently been reported to have a critical role *in vivo*, were investigated by measuring *CYP3A4* protein expression levels and *CYP3A4*-dependent drug oxidation activities in individual human liver microsomes *in vitro*. Prior to protein analysis, analysis of DNA samples indicated that 36 Caucasian subjects were genotyped as *CYP3A4*1/*1* and five subjects were *CYP3A4*1/*22*, with a *CYP3A4*22* allelic frequency of 6.1%. No *CYP3A4*22* alleles were found in the Japanese samples (106 alleles). Individual differences in *CYP2D6*-dependent dextromethorphan *O*-demethylation activities in liver microsomes from Caucasians were not affected by either the *CYP3A4*1/*22* or *CYP3A5*1/*3* genotype. Liver microsomes genotyped as *CYP3A4*1/*22* (n=4) showed significantly lower *CYP3A*-dependent dextromethorphan *N*-demethylation, midazolam 1'-hydroxylation, and testosterone 6β-hydroxylation activities, as well as lower expression levels of *CYP3A* protein (28% of control), compared with those of the *CYP3A4*1/*1* group (n=19). The other polymorphism, *CYP3A5*1/*3*, did not show these differences (n=4). The *CYP3A4*22* polymorphism was associated with reduced *CYP3A4* protein expression levels and resulted in decreased *CYP3A4*-dependent activities in human livers. The present results suggest an important role of low expression of *CYP3A4* protein associated with the *CYP3A4*22* allele in the individual differences in drug clearance.

Keywords

P450 3A4; P450 3A5; protein expression; ethnic difference; impaired polymorphism

*To whom correspondence should be addressed (H.Y.) at Showa Pharmaceutical University, Machida, Tokyo 194-8543, Japan. Tel/Fax: +81-42-721-1406, hyamazaki@ac.shoyaku.ac.jp.

Introduction

Cytochrome P450 (P450 or CYP) comprises a superfamily of enzymes and plays an important role in the oxidative metabolism of a large number of endogenous and exogenous compounds (Guengerich 2008). CYP3A4 is the most abundant P450 enzyme in human livers and is involved in metabolism of > 50% of marketed drugs (Rendic 2002; Shimada *et al.*, 1994). CYP3A activity has been shown to display 10- to 100-fold variation among individuals (Lamba *et al.*, 2002; Shimada *et al.*, 1994; Westlind *et al.*, 1999; Westlind-Johnsson *et al.*, 2003), which may influence drug response and toxicity. Low drug clearances mediated by impaired CYP3A4 would invoke unexpected side effects or drug interactions with co-administered food or medicines. It has been suggested that ~85% of the inter-individual variability in hepatic CYP3A4 expression and activity is attributable to genetic factors (Ozdemir *et al.*, 2000). However, most of the *CYP3A4* polymorphisms examined to date have low frequencies (<http://www.cypalleles.ki.se/cyp3a4.htm>). The most common *CYP3A4* variant has been a promoter variant (*CYP3A4*1B*) leading to modified CYP3A4 activity (Garcia-Martin *et al.*, 2002), but subsequent work on this has not been clear regarding its significance (Ball *et al.*, 1999; Garcia-Martin *et al.*, 2002).

A recent study identified a functional SNP in *CYP3A4* intron 6 (rs35599367C>T; *CYP3A4*22*) (Wang *et al.*, 2011). The *CYP3A4*22* genotype is associated with a good lipid-lowering response to the drug simvastatin (Elens *et al.*, 2011a). In addition, renal transplant patients with the *CYP3A4*22* allele show reduced clearance of a calcineurin inhibitor and therefore might be associated with increased risk of drug overexposure (Elens *et al.*, 2011b; Elens *et al.*, 2011c; Elens *et al.*, 2012). However, there are no clear *in vitro* reports regarding any effects of the *CYP3A4*22* allele on protein levels. On the other hand, CYP3A5, demonstrating 84% amino acid sequence identity with CYP3A4, has been associated with the metabolism of a variety of CYP3A4-probe drugs (Wrighton *et al.*, 1992). The most frequent variant of functional importance in the *CYP3A5* gene has been *CYP3A5*3*, leading to alternative splicing with impaired protein expression (Kuehl *et al.*, 2001; van Schaik *et al.*, 2002). Therefore, *CYP3A5* polymorphisms should also have potential effects on CYP3A-dependent activities in human livers. However, there are no available studies to clarify the *CYP3A4*22* and *CYP3A5*3* polymorphisms, in combination, on the catalytic function in human liver microsomes.

In the present study, effects of the *CYP3A4*22* and *CYP3A5*3* polymorphisms were investigated by measuring CYP3A protein expression levels and CYP3A-dependent drug oxidation in individual human livers. Ethnic differences of the frequency of the *CYP3A4*22* allele were seen between Caucasian and Japanese subjects. We report, for the first time, a clear association between the *CYP3A4*22* polymorphism, CYP3A4 protein levels, and catalytic function in human liver microsomes.

Materials and Methods

Chemicals

Dextromethorphan was obtained from Sigma-Aldrich (St. Louis, MO). Midazolam and testosterone were obtained from Wako Pure Chemicals (Osaka, Japan). Other chemicals and

reagents used in this study were obtained from the sources described previously and were of the highest quality commercially available (Yamazaki *et al.*, 2002; Yamazaki *et al.*, 2006).

Enzyme preparations

The use of the human livers for this study was approved by the Ethics Committees of Vanderbilt University School of Medicine and Showa Pharmaceutical University. The human livers (5– to 74-year-old males and females) were obtained from patients after pathological examination of specimens isolated during hepatic surgery or after death (Inoue *et al.*, 1997; Shimada *et al.*, 2001; Yamaori *et al.*, 2004; Yamaori *et al.*, 2005; Yamazaki *et al.*, 2003). Human liver microsomes were prepared in 10 mM Tris-HCl buffer (pH 7.4) containing 0.10 mM EDTA and 20% (v/v) glycerol as described previously (Yamaori *et al.*, 2005).

Genotyping

Genomic DNA was isolated from human livers as previously described (Inoue *et al.*, 1997; Shimada *et al.*, 2001; Yamaori *et al.*, 2004; Yamaori *et al.*, 2005; Yamazaki *et al.*, 2003). The *CYP3A4**22 genotype was determined with 10 ng genomic of DNA in an allelic discrimination reaction performed with TaqMan® (Applied Biosystems, Foster City, CA, USA) genotyping assays (C_59013445_10) using a 7300 Real Time PCR System® (Applied Biosystems). The *CYP3A5**3 genotype was determined according to a previously published method (Adler *et al.*, 2009).

Enzyme assays

Microsomal protein concentrations were estimated using a bicinchoninic acid protein assay kit (Pierce, Rockford, IL). Activities for *O*- and *N*-demethylation of dextromethorphan, 1'-hydroxylation of midazolam, and 6 β -hydroxylation of testosterone were assayed according to described methods (Kronbach *et al.*, 1989; Uno *et al.*, 2010; Yamazaki *et al.*, 1997). Briefly, the standard incubation mixtures consisted of 100 mM potassium phosphate buffer (pH 7.4), an NADPH-generating system (0.25 mM NADP⁺, 2.5 mM glucose 6-phosphate, and 0.25 unit/ml glucose 6-phosphate dehydrogenase), a substrate (400 μ M dextromethorphan, 100 μ M midazolam, or 50 μ M testosterone), and liver microsomes (0.20–0.50 mg protein/ml) in a final volume of 0.25 ml. Dextromethorphan and midazolam were incubated with microsomes at 37°C for 15 min and terminated by the addition of 10 μ l of 60% perchloric acid (w/v) or 0.25 ml of ice-cold methanol. Testosterone oxidation reactions were incubated at 37 °C for 10 min and terminated by the addition of 1.5 ml of ethyl acetate and 25 μ l of 3 M sodium chloride. After extraction, the organic phase of each sample was evaporated under a nitrogen stream. Product formation was determined by high-performance liquid chromatography with an analytical octadecylsilane (C₁₈) column (4.6 mm $\times$ 150 mm, 5 μ m) according to described methods (Kronbach *et al.*, 1989; Uno *et al.*, 2010; Yamazaki *et al.*, 1997).

Western blot analysis

SDS-PAGE was performed using 7.5% (w/v) acrylamide gels. Microsomal protein (5 μ g) was separated and transferred onto a nitrocellulose membrane. Immunoblot quantitation was

performed using recombinant CYP3A4 (Supersomes, BD Gentest, Franklin Lakes, NJ, USA) and a mouse antibody to human CYP3A (BD Gentest) as the standard protein and primary antibody for both human CYP3A4 and CYP3A5, respectively. Horseradish peroxidase-conjugated anti-mouse immunoglobulin (BD Gentest) was used as a secondary antibody (Yamaori *et al.*, 2004). A specific band was visualized using LAS-1000UVmini (GE Healthcare, Tokyo, Japan) and analyzed using Multi Gauge software, version 3.0 (GE Healthcare).

Statistical analyses

Statistical analysis was performed by Prism software, version 5.01 (GraphPad, San Diego, CA, USA). The differences in enzymatic activities between two genotypes were evaluated using an unpaired *t*-test with Welch correction. Statistical tests provided two-sided *p* values with a significance level of < 0.05 .

Results

DNA samples from 41 Caucasian and 53 Japanese subjects were genotyped for *CYP3A4* using a TaqMan assay method (Table 1). Among the Caucasian samples, 36 subjects were genotyped as *CYP3A4**1/*1 but five subjects were of the *CYP3A4**1/*22 genotype. The *CYP3A4**22 allelic frequency was estimated to be 6.1% in this sample, similar to that reported previously in Caucasians (Elens *et al.*, 2011b). On the other hand, there were no *CYP3A4**22 alleles observed in our Japanese samples (106 alleles). The expected frequency of the *CYP3A4**22 in a Japanese population was calculated to be $< 1\%$; further analysis may be important in this context.

To investigate the effects of genetic polymorphism of the *CYP3A4* and *CYP3A5* genes on the metabolic activities, dextromethorphan *O*- and *N*-demethylation, midazolam 1'-hydroxylation, and testosterone 6 β -hydroxylation activities were determined in liver microsomes prepared from 23 Caucasian subjects genotyped for *CYP3A4* (19 *CYP3A4**1/*1 and four *CYP3A4**1/*22) and *CYP3A5* (four *CYP3A5**1/*3 and 19 *CYP3A5**3/*3). There were no examples of both *CYP3A4**22 and *CYP3A5**1 among these liver samples. CYP2D6-dependent catalytic activities (dextromethorphan *O*-demethylation) in liver microsomes did not differ between both the *CYP3A4* and *CYP3A5* genotypes (Figure 1A). On the other hand, the heterozygote group consisted of four liver microsomal preparations derived from subjects genotyped as *CYP3A4**1/*22 (and also *CYP3A5**3/*3) showed significantly lower CYP3A-dependent activities (*N*-demethylation of dextromethorphan, 1'-hydroxylation of midazolam, and 6 β -hydroxylation of testosterone), compared with the wild-type (*CYP3A4**1/*1) group (Figure 1B–D, **p* < 0.05 and ***p* < 0.01). Although these typical substrates of CYP3A are also metabolized by CYP3A5, the *CYP3A5* genotype did not show any significant differences under the present experimental conditions (Figure 1). CYP3A protein contents in liver microsomes from subjects genotyped as *CYP3A4**1/*22 were significantly lower (28% of control) than from subjects genotyped as *CYP3A4**1/*1, while there was no significant differences between *CYP3A5* genotypes (Figure 2). The individuals in the *CYP3A4**1/*22 heterozygote group were all genetically poor expressers of CYP3A5 in this study.

Discussion

A *CYP3A4* intron 6 C>T (*CYP3A4**22) allele (Elens *et al.*, 2011a; Elens *et al.*, 2011b; Elens *et al.*, 2011c; Wang *et al.*, 2011) is associated with reduced *CYP3A4* activity *in vivo*. Wang *et al.* have recently reported that *CYP3A4**22 is linked to reduced *CYP3A4* mRNA production (without any splice variants) and limited testosterone 6 β -hydroxylation activity in human livers. However, the finding regarding *CYP3A4* mRNA levels has not been strongly supported by the recent study (Klein *et al.*, 2012). Although statistically significant decreases of area-under the curve of drug metabolites per variant allele has been strongly confirmed in the *in vivo* cohort (Klein *et al.*, 2012), we are not aware of clear *in vitro* reports of studies regarding any effects of the *CYP3A4**22 allele on protein levels and multiple enzymatic function.

In the present study, decreased *CYP3A* protein contents (28% of control) in human liver microsomes associated with the *CYP3A4**22 genotype were clearly shown for the first time, using a mouse anti-human *CYP3A* antibody (Figure 2). Under the present condition, *CYP3A5* could be detected, along with *CYP3A4* in liver microsomes; however, most Caucasians are genetically poor expressers of *CYP3A5* (*CYP3A5**3/*3) (Kuehl *et al.*, 2001; van Schaik *et al.*, 2002). In the four Caucasian liver samples that were heterozygous expressers of *CYP3A5*, these levels were low and < ~5 pmol *CYP3A5*/mg protein (Yamaori *et al.*, 2005; Yamazaki *et al.*, 1995). Reduced *CYP3A4* protein expression levels resulted in decreased *CYP3A4*-mediated enzymatic activities in liver microsomal samples derived from Caucasians (24–50% of controls, an average of 37%, shown in Figure 1). Consequently, these results regarding impaired metabolic function in liver microsomes *in vitro* caused by the *CYP3A4**22 genotype could support the recent reported findings of low clearance of clinical *CYP3A*-related drugs *in vivo* (Elens *et al.*, 2011a; Elens *et al.*, 2011b; Elens *et al.*, 2011c; Elens *et al.*, 2013; Wang *et al.*, 2011). The reason why this *CYP3A4**22 polymorphism in the intronic part of the gene can lead to lowered the mRNA and/or protein expression should be investigated in the future.

In conclusion, the *CYP3A4**22 allele was associated with decreased *CYP3A4* protein expression levels and resulted in decreased *CYP3A4*-mediated enzymatic activities. These results suggest an important role of low expression of *CYP3A4* protein associated with this *CYP3A4**22 allele in the individual differences in drug clearance in Caucasians. Drug therapy for the Caucasian patients harboring the *CYP3A4**22 allele with *CYP3A4*-dependent drugs should be paid attention. Furthermore, it was also demonstrated that the frequency of the *CYP3A4**22 allele shows ethnic differences. Shi *et al.* have recently reported that they found no *CYP3A4**22 alleles in 216 Chinese subjects. Because no *CYP3A4**22 allele carriers were found in a Japanese population in the present study, it may be implied that the effects of *CYP3A4**22 polymorphism might be limited in Japanese subjects, which show a wide variety of inter-individual differences in inductive *CYP3A4*-dependent drug disposition.

Acknowledgments

This work was supported in part by the Ministry of Education, Science, Sports and Culture of Japan, the Takeda Science Foundation, and the United States Public Health Service (R37 CA090426).

References

- Adler G, Loniewska B, Parczewski M, Kordek A, Ciechanowicz A. Frequency of common CYP3A5 gene variants in healthy Polish newborn infants. *Pharmacol Rep.* 2009; 61:947–951. [PubMed: 19904021]
- Ball SE, Scatina J, Kao J, Ferron GM, Fruncillo R, Mayer P, Weinryb I, Guida M, Hopkins PJ, et al. Population distribution and effects on drug metabolism of a genetic variant in the 5' promoter region of CYP3A4. *Clin Pharmacol Ther.* 1999; 66:288–294. [PubMed: 10511065]
- Elens L, Becker ML, Haufroid V, Hofman A, Visser LE, Uitterlinden AG, Stricker B, van Schaik RH. Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study. *Pharmacogenet Genomics.* 2011; 21:861–866. [PubMed: 21946898]
- Elens L, Bouamar R, Hesselink DA, Haufroid V, van der Heiden IP, van Gelder T, van Schaik RH. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. *Clin Chem.* 2011; 57:1574–1583. [PubMed: 21903774]
- Elens L, van Schaik RH, Panin N, de Meyer M, Wallemacq P, Lison D, Mourad M, Haufroid V. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients. *Pharmacogenomics.* 2011; 12:1383–1396. [PubMed: 21902502]
- Elens L, Bouamar R, Hesselink DA, Haufroid V, van Gelder T, van Schaik RH. The new CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients. *Pharmacogenet Genomics.* 2012; 22:373–380. [PubMed: 22388796]
- Elens L, Nieuweboer A, Clarke SJ, Charles KA, de Graan AJ, Haufroid V, Mathijssen RH, van Schaik RH. CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin. *Pharmacogenomics.* 2013; 14:137–149. [PubMed: 23327575]
- Garcia-Martin E, Martinez C, Pizarro RM, Garcia-Gamito FJ, Gullsten H, Raunio H, Agundez JA. CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity. *Clin Pharmacol Ther.* 2002; 71:196–204. [PubMed: 11907494]
- Guengerich FP. Cytochrome P450 and chemical toxicology. *Chem Res Toxicol.* 2008; 21:70–83. [PubMed: 18052394]
- Inoue K, Yamazaki H, Imiya K, Akasaka S, Guengerich FP, Shimada T. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations. *Pharmacogenetics.* 1997; 7:103–113. [PubMed: 9170147]
- Klein K, Thomas M, Winter S, Nussler AK, Niemi M, Schwab M, Zanger UM. *PPARA* : a novel genetic determinant of CYP3A4*in vitro* and*in vivo* . *Clin Pharmacol Ther.* 2012; 91:1044–1052. [PubMed: 22510778]
- Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA. Oxidation of midazolam and triazolam by human liver cytochrome P450III A4. *Mol Pharmacol.* 1989; 36:89–96. [PubMed: 2787473]
- Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. *Nat Genet.* 2001; 27:383–391. [PubMed: 11279519]
- Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. *Adv Drug Deliv Rev.* 2002; 54:1271–1294. [PubMed: 12406645]
- Ozdemir V, Kalow W, Tang BK, Paterson AD, Walker SE, Endrenyi L, Kashuba AD. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. *Pharmacogenetics.* 2000; 10:373–388. [PubMed: 10898107]
- Rendic S. Summary of information on human CYP enzymes: human P450 metabolism data. *Drug Metab Rev.* 2002; 34:83–448. [PubMed: 11996015]
- Shi Y, Li Y, Tang J, Zhang J, Zou Y, Cai B, Wang L. Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients. *Gene.* 2013; 512:226–231. [PubMed: 23107770]

- Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. *J Pharmacol Exp Ther*. 1994; 270:414–423. [PubMed: 8035341]
- Shimada T, Tsumura F, Yamazaki H, Guengerich FP, Inoue K. Characterization of (+/-)-bufuralol hydroxylation activities in liver microsomes of Japanese and Caucasian subjects genotyped for CYP2D6. *Pharmacogenetics*. 2001; 11:143–156. [PubMed: 11266079]
- Uno Y, Uehara S, Kohara S, Murayama N, Yamazaki H. Cynomolgus monkey CYP2D44, newly identified in liver, metabolizes bufuralol, and dextromethorphan. *Drug Metab Dispos*. 2010; 38:1486–1492. [PubMed: 20501912]
- van Schaik RH, van der Heiden IP, van den Anker JN, Lindemans J. CYP3A5 variant allele frequencies in Dutch Caucasians. *Clin Chem*. 2002; 48:1668–1671. [PubMed: 12324482]
- Wang D, Guo Y, Wrighton SA, Cooke GE, Sadee W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. *Pharmacogenomics J*. 2011; 11:274–286. [PubMed: 20386561]
- Westlind A, Lofberg L, Tindberg N, Andersson TB, Ingelman-Sundberg M. Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5'-upstream regulatory region. *Biochem Biophys Res Commun*. 1999; 259:201–205. [PubMed: 10334940]
- Westlind-Johnsson A, Malmbo S, Johansson A, Otter C, Andersson TB, Johansson I, Edwards RJ, Boobis AR, Ingelman-Sundberg M. Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. *Drug Metab Dispos*. 2003; 31:755–761. [PubMed: 12756208]
- Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. *Crit Rev Toxicol*. 1992; 22:1–21. [PubMed: 1616599]
- Yamaori S, Yamazaki H, Iwano S, Kiyotani K, Matsumura K, Honda G, Nakagawa K, Ishizaki T, Kamataki T. CYP3A5 contributes significantly to CYP3A-mediated drug oxidations in liver microsomes from Japanese subjects. *Drug Metab Pharmacokinet*. 2004; 19:120–129. [PubMed: 15499178]
- Yamaori S, Yamazaki H, Iwano S, Kiyotani K, Matsumura K, Saito T, Parkinson A, Nakagawa K, Kamataki T. Ethnic differences between Japanese and Caucasians in the expression levels of mRNAs for CYP3A4, CYP3A5 and CYP3A7: lack of co-regulation of the expression of CYP3A in Japanese livers. *Xenobiotica*. 2005; 35:69–83. [PubMed: 15788369]
- Yamazaki H, Inui Y, Wrighton SA, Guengerich FP, Shimada T. Procarcinogen activation by cytochrome P450 3A4 and 3A5 expressed in *Escherichia coli* and by human liver microsomes. *Carcinogenesis*. 1995; 16:2167–2170. [PubMed: 7554070]
- Yamazaki H, Shimada T. Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. *Arch Biochem Biophys*. 1997; 346:161–169. [PubMed: 9328296]
- Yamazaki H, Nakamura M, Komatsu T, Ohya K, Hatanaka N, Asahi S, Shimada N, Guengerich FP, Shimada T, et al. Roles of NADPH-P450 reductase and apo- and holo-cytochrome b5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of *Escherichia coli*. *Protein Expr Purif*. 2002; 24:329–337. [PubMed: 11922748]
- Yamazaki H, Kiyotani K, Tsubuko S, Matsunaga M, Fujieda M, Saito T, Miura J, Kobayashi S, Kamataki T. Two novel haplotypes of CYP2D6 gene in a Japanese population. *Drug Metab Pharmacokinet*. 2003; 18:269–271. [PubMed: 15618746]
- Yamazaki H, Okayama A, Imai N, Guengerich FP, Shimizu M. Inter-individual variation of cytochrome P4502J2 expression and catalytic activities in liver microsomes from Japanese and Caucasian populations. *Xenobiotica*. 2006; 36:1201–1209. [PubMed: 17162467]

Fig. 1. Association between *CYP3A4* and *CYP3A5* genotypes and P450-dependent drug oxidation activities in human liver microsomes

Dextromethorphan *O*- (A) and *N*-demethylation (B), midazolam 1'-hydroxylation (C), and testosterone 6 β -hydroxylation (D) activities were analyzed in liver microsomal samples from 23 Caucasians genotyped for *CYP3A4* and *CYP3A5*. The horizontal lines indicate the mean activities, respectively. * $p < 0.05$; ** $p < 0.01$, significantly different by unpaired *t*-test with Welch correction.

Fig. 2. Association between *CYP3A4* and *CYP3A5* genotypes and expression levels of CYP3A protein in human liver microsomes
 CYP3A contents were measured in liver microsomal samples from 23 Caucasians genotyped for *CYP3A4* and *CYP3A5* by immunoblotting. * $p < 0.05$, significantly different by unpaired t -test with Welch correction.

Table 1*CYP3A4* allele frequencies in 41 Caucasian and 53 Japanese DNA samples

<i>3A4</i> allele	Number (%)	
	Caucasian n=82	Japanese n=106
*1	77 (94)	106 (100)
*22	5 (6)	0 (0)